Zimmer Biomet commenced international release of the Subchondroplasty® procedure (SCP®), following its approval under the CE Mark. ZBH also received approval for distribution in Canada, Hong Kong, Malaysia and Singapore.
The minimally invasive outpatient procedure addresses defects associated with subchondral bone marrow lesions. SCP fills the chronic lesions with AccuFill® Bone Substitute, a porous injectable calcium phosphate, which is resorbed and replaced with healthy bone.
Subchondroplasty has remained a consistently-cited contributor to growth for Zimmer Biomet. Initially used in bone defects of the knee, the SCP Procedure has been successfully performed in other areas including the foot, ankle and hip. ZBH owns 36 patents and eight trademarks in this area, with others pending.
Zimmer Biomet commenced international release of the Subchondroplasty® procedure (SCP®), following its approval under the CE Mark. ZBH also received approval for distribution in Canada, Hong Kong, Malaysia and Singapore.
The minimally invasive outpatient procedure addresses defects associated with subchondral bone marrow lesions. SCP fills the...
Zimmer Biomet commenced international release of the Subchondroplasty® procedure (SCP®), following its approval under the CE Mark. ZBH also received approval for distribution in Canada, Hong Kong, Malaysia and Singapore.
The minimally invasive outpatient procedure addresses defects associated with subchondral bone marrow lesions. SCP fills the chronic lesions with AccuFill® Bone Substitute, a porous injectable calcium phosphate, which is resorbed and replaced with healthy bone.
Subchondroplasty has remained a consistently-cited contributor to growth for Zimmer Biomet. Initially used in bone defects of the knee, the SCP Procedure has been successfully performed in other areas including the foot, ankle and hip. ZBH owns 36 patents and eight trademarks in this area, with others pending.
Copy to clipboard 
